SCHEMBL2182121

SCHEMBL2182121

CCN(CC)CCOc1ccc(/C=N/N(C)c2cc(=O)n(C)c(=O)[nH]2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.61
KDM4C Q9H3R0 2/20 0.61
ALDH1A1 P00352 4/20 0.56
HPGD P15428 3/20 0.56
NR1I2 O75469 1/20 0.56
AHR P35869 1/20 0.56
PKM P14618 2/20 0.55
LMNA P02545 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.53
THRB P10828 2/20 0.49
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42
ADORA1 P30542 1/20 0.42
KCNH2 Q12809 1/20 0.42
MCHR1 Q99705 1/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 1/20 0.42
CHRNA7 P36544 1/20 0.42
FLT3 P36888 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2182123 1.00 KDM4E (0.61) KDM4EKDM4CALDH1A1HPGDNR1I2
SCHEMBL2184654 0.86 ALDH1A1 (0.60) KDM4EKDM4CALDH1A1HPGDNR1I2
SCHEMBL2184660 0.86 ALDH1A1 (0.60) KDM4EKDM4CALDH1A1HPGDNR1I2
SCHEMBL2179274 0.84 KDM4E (0.75) KDM4EKDM4CALDH1A1HPGDNR1I2
SCHEMBL2179271 0.84 KDM4E (0.75) KDM4EKDM4CALDH1A1HPGDNR1I2
SCHEMBL2181477 0.79 KDM4E (0.67) KDM4EKDM4CALDH1A1HPGDNR1I2
SCHEMBL2181480 0.79 KDM4E (0.67) KDM4EKDM4CALDH1A1HPGDNR1I2
SCHEMBL2179941 0.79 KDM4E (0.67) KDM4EKDM4CALDH1A1HPGDNR1I2
SCHEMBL2179940 0.79 KDM4E (0.67) KDM4EKDM4CALDH1A1HPGDNR1I2
SCHEMBL2181297 0.76 KDM4E (0.62) KDM4EKDM4CALDH1A1HPGDNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same DPYD, TYMP, DHFR KDM4E 4180/4885KDM4C 3280/4885ALDH1A1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.